Spots Global Cancer Trial Database for ovarian serous surface papillary adenocarcinoma

Every month we try and update this database with for ovarian serous surface papillary adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	NCT01116648	Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Ovarian Serous ... Ovarian Serous ... Primary Periton... Triple-Negative...	Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
Research Study in Patients With Advanced Ovarian Epithelial Cancer	NCT00053235	Ovarian Serous ... Ovarian Serous ... Stage IIIA Ovar... Stage IIIB Ovar... Stage IIIC Ovar... Stage IV Ovaria...	Comparative Gen... Laboratory Biom... Polymerase Chai...	-	GOG Foundation
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer	NCT01010126	Adult Hepatocel... Advanced Adult ... Endometrial Ser... Localized Non-R... Lung Carcinoid ... Malignant Pancr... Malignant Pancr... Malignant Pancr... Malignant Pancr... Metastatic Dige... Ovarian Carcino... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Pancreatic Alph... Pancreatic Beta... Pancreatic Delt... Pancreatic G-Ce... Pancreatic Poly... Recurrent Adult... Recurrent Diges... Recurrent Fallo... Recurrent Ovari... Recurrent Pancr... Recurrent Prima... Recurrent Uteri... Regional Digest... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIA Uter... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIB Uter... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IIIC Uter... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... Stage IVA Uteri... Stage IVB Uteri... Uterine Carcino...	Bevacizumab Temsirolimus	18 Years -	National Cancer Institute (NCI)
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02101775	Ovarian Brenner... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Adavosertib Gemcitabine Hyd... Laboratory Biom... Pharmacological... Placebo Adminis... Questionnaire A...	18 Years -	National Cancer Institute (NCI)
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer	NCT02283658	Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Undifferentiate...	Everolimus Laboratory Biom... Letrozole	18 Years -	Mayo Clinic
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	NCT01116648	Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Ovarian Serous ... Ovarian Serous ... Primary Periton... Triple-Negative...	Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib	18 Years -	National Cancer Institute (NCI)
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer	NCT02283658	Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... Undifferentiate...	Everolimus Laboratory Biom... Letrozole	18 Years -	Mayo Clinic
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	NCT02101775	Ovarian Brenner... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Prima...	Adavosertib Gemcitabine Hyd... Laboratory Biom... Pharmacological... Placebo Adminis... Questionnaire A...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: